Synosia Therapeutics develops and intends to commercialise innovative, first or best-in-class products for unmet medical needs in neurology and psychiatry. We utilise cutting edge technologies and creative clinical study designs to de-risk our compounds before moving into larger, more extensive Phase II and Phase III programmes. We currently have five clinical-stage compounds in development for neurological and psychiatric diseases that have high unmet medical need, including Parkinson’s disease and Alzheimer’s disease. For doctors, this means potential new treatment options for debilitating neurological conditions. For patients, it could mean vast improvements in quality of life.